I claim:

A nucleoside of the formula 1.

HOHZC

PSC

wherein R is a base of the

10~

15

20

25

5

10

15

20

PS PO

po B

10500

10501+

25

methyl.

wherein

or iodo;

R¹ is hydrogen, methyl, bromo, fluoro, chloro

R² is hydroxy or amino;

R³ is hydrogen, bromo, chloro or iodo.

2. A nucleoside of <u>claim_l</u>, wherein the carbohydrate moiety is in the ribose form.

3. A nucleoside of claim 2 wherein the base is of the formula

H N3 5 R

4. A nucleoside of claim 1 wherein the base is of the formula

H N3 5 R

5. A nucleoside of claim A wherein R¹ is

6. A nucleoside of claim 3 wherein \mathbb{R}^1 is methyl.

7. A nucleoside of claim 1 wherein the base is of the formula


70510 X 5

ŅНа

10 A nucleoside of claim 2 wherein the base is of the formula

T0511X

15



A nucleoside of claim wherein R¹ is

20 iodo.

A nucleoside of claim_8 wherein R¹ is 10. iodo.

A method of treating viral infections in mammals comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim_1.

A pharmaceutical composition comprising a 12. compound of claim 1 and a pharmaceutically-acceptable carrier, diluent or excipient therefor.

5

15

20

25

13. A difluoro-desoxy carbohydrate of the formula

Y0H2C 4 1 1 X

wherein X is hydroxy or a leaving group; and the Y

10 groups independently are hydrogen or hydroxy-protecting
groups.

14. A carbohydrate of claim 13 which is in the ribose form.

15. A carbohydrate of claim 14 wherein X is hydroxy.

16. A carbohydrate of claim 13 wherein X is hydroxy.

17. A carbohydrate of claim 15 wherein Y is hydrogen.

18. A carbohydrate of claim 16 wherein Y is hydrogen.

19. A carbohydrate of claim 13 wherein X is a sulfonate leaving group.

20. A carbohydrate of claim 14 wherein X is a sulfonate leaving group.

21. A carbohydrate of claim 19 wherein Y is a silyl hydroxy-protecting group.

22. A carbohydrate of claim 20 wherein Y is a silyl hydroxy-protecting group.

all 2